Search

Your search keyword '"Waterhouse, David"' showing total 749 results
Start Over Author "Waterhouse, David"
749 results on '"Waterhouse, David"'

6. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Author

Bastick, Patricia, Sewak, Sanjeev, Tran, Ben, Pichler, Martin, Shariat, Shahrokh, Rottey, Sylvie, Schatteman, Peter, Schrijvers, Dirk, Verschaeve, Vincent, Vulsteke, Christof, Barros Leite Ferreira, Luiza Aleixo, de Santana Gomes Andrea Juliana, Pereira, Junior, Joao Antonio, Azevedo, Sergio, Bastos, Diogo, Borges, Giuliano, Dettino, Aldo, Antonio, Pires Luis, Luz, Murilo, Martins, Suelen, Mota, Jose Mauricio, Toledo, Joseane, Eigl, Bernhard, Finch, Daygen, Gingerich, Joel, Dong, Haiying, Huang, Jian, Jin, Jie, Pan, Hongming, Sun, Zhongquan, Tian, Ye, Wan, Ben, Wu, Bin, Xu, Ting, Xue, Wei, Zhou, Fangjian, Barthelemy, Philippe, Borchiellini, Delphine, Calcagno, Fabien, Carnot, Aurelien, Cornillon, Pierre, Delva, Remy, Emambux, Sheik, Houede, Nadine, Laguerre, Brigitte, Lauridant, Géraldine, Loriot, Yohann, Mahammedi, Hakim, Maillet, Denis, Pouessel, Damien, Roubaud, Guilhem, Schlurmann-Constans, Friederike, Tosi, Diego, Zanetta, Sylvie, Banek, Severine, Feyerabend, Susan, Kramer, Mario, Niegisch, Guenther, Nuhn, Philipp, Schnabel, Marco, Wuelfing, Christian, Baka, Sofia, Bamias, Aristotelis, Fountzilas, George, Kalofonos, Harabolos, Karalis, Konstantinos, Kotsakis, Athanasios, Timotheadou, Eleni, Landherr, Laszlo, Mangel, Laszlo, Pe’er, Avivit, Levratovsky, Meital, Basso, Umberto, Battelli, Nicola, Cavo, Alessia, De Giorgi, Ugo, Doni, Laura, Galli, Luca, Gigante, Maria Olga, Guadalupi, Valentina, Maio, Michele, Milesi, Laura, Nolè, Franco, Scagliotti, Giorgio, Tortora, Giampaolo, Fukasawa, Satoshi, Harabayashi, Toru, Kamiya, Naoto, Kawahara, Takashi, Kawakita, Mutsushi, Matsubara, Nobunaki, Matsumoto, Kazumasa, Nishimura, Kazuo, Rikiya, Taoka, Shimizu, Nobuaki, Tagaki, Toshio, Kang, Taek Won, Kim, Jwa Hoon, Kim, SeHyun, Lee, Hyo Jin, Lee, Yun-Gyoo, Rha, Sun Young, Seo, Ho Kyung, Los, Maartje, Zurawski, Bogdan, Cortes, Paulo, Faustino, Catia, Vau, Nuno Sineiro, da Luz, Ricardo, Atduev, Vagif, Kirtbaya, Dmitry, Kopyltsov, Evgeny, Lykov, Aleksandr, Marat, Urmantsev, Orlov, Sergey, Penkov, Konstantin, Pirmagomedov, Albert, Semenov, Andrey, Varlamov, Sergey, Anguera, Georgia, Domenech, Montserrat, Girones, Regina, Gonzalez del Alba, Aranzazu, Milagro, Nuria Lainez, Luque, Raquel, Ortega, Esther Martínez, Mellado, Begoña, Méndez Vidal, María Jose, Fernandez, Esteban Nogales, Valderrama, Begoña Perez, Marín, Alvaro Pinto, Santander, Carmen, Huang, Yi-Hsiu, Su, Wen-Pin, Wu, Hung-Chan, Wu, WenJeng, Yu, Kai-Jie, Bilici, Ahmet, Goker, Erdem, Gumus, Mahmut, Karaoglu, Aziz, Kefeli, Umut, Köse, Fatih, Ozguroglu, Mustafa, Tural, Deniz, Turk, Haci, Yalcin, Suayib, Bondarenko, Igor, Khareba, Gennadii, Kidik, Yana, Lychkovskyy, Oleksandr, Sakalo, Valerii, Shevnia, Serghii, Stakhovskyy, Eduard, Bahl, Amit, Crabb, Simon, Powles, Thomas, Sankey, Peter, Sarwar, Mohammad, Benedetto, Pasquale, Burgess, Earle, Dawson, Nancy, Doshi, Gurjyot, Fleming, Mark, Maly, Joseph, Parikh, Mamta, Waterhouse, David, Siefker-Radtke, A.O., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Özgüroğlu, M., Valderrama, B.P., Laguerre, B., Basso, U., Triantos, S., Akapame, S., Kean, Y., Deprince, K., Mukhopadhyay, S., and Loriot, Y.

Published
2024
Full Text
View/download PDF

8. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy

Author

He, Kai, Berz, David, Gadgeel, Shirish M., Iams, Wade T., Bruno, Debora S., Blakely, Collin M., Spira, Alexander I., Patel, Manish R., Waterhouse, David M., Richards, Donald A., Pham, Anthony, Jotte, Robert, Hong, David S., Garon, Edward B., Traynor, Anne, Olson, Peter, Latven, Lisa, Yan, Xiaohong, Shazer, Ronald, and Leal, Ticiana A.

Published
2023
Full Text
View/download PDF

9. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Author

de Langen, Adrianus Johannes, Johnson, Melissa L, Mazieres, Julien, Dingemans, Anne-Marie C, Mountzios, Giannis, Pless, Miklos, Wolf, Jürgen, Schuler, Martin, Lena, Hervé, Skoulidis, Ferdinandos, Yoneshima, Yasuto, Kim, Sang-We, Linardou, Helena, Novello, Silvia, van der Wekken, Anthonie J, Chen, Yuanbin, Peters, Solange, Felip, Enriqueta, Solomon, Benjamin J, Ramalingam, Suresh S., Dooms, Christophe, Lindsay, Colin R, Ferreira, Carlos Gil, Blais, Normand, Obiozor, Cynthia C, Wang, Yang, Mehta, Bhakti, Varrieur, Tracy, Ngarmchamnanrith, Gataree, Stollenwerk, Björn, Waterhouse, David, and Paz-Ares, Luis

Published
2023
Full Text
View/download PDF

10. Pharmacokinetic-pharmacodynamic modelling of anti-Wolbachia agents

Author

Waterhouse, David

Subjects
614.5
Abstract

Lymphatic filariasis (LF) and onchocerciasis are priority neglect tropical disease that together infect more than 84 million people worldwide, with an at-risk population of 1.5 billion people, meaning the need for mass drug administration programmes over sustained period of time is a must. Current and historical chemotherapeutic approaches to LF and onchocerciasis control have relied heavily upon drugs with only microfilaricidal activity. Failure to develop a macrofilaricide capable of being deployed within the mass drug administration (MDA) environment has led to an over reliance on the current frontline drugs of ivermectin, albendazole and diethylcarbamazine. The formation of the anti-Wolbachia (AWOL) consortium was conceived to meet the urgent global need for a safe and reliable macrofilaricidal drug that can accelerate the elimination programmes currently being deployed for the treatment of LF and onchocerciasis. The AWOL consortium demonstrated that by targeting the obligated endosymbiont bacteria Wolbachia with doxycycline (DOX) treatment, a safe macrofilaricidal activity could be delivered that demonstrated superior therapeutic outcomes in comparison to current standard anti-filarial drugs (SAFD). The establishment of DOX as a novel treatment regimen for filarial nematode infections is constrained as DOX is contraindicated in children under eight years old and in pregnancy. The purpose of this thesis is to find an anti-Wolbachia based treatment regimen that is suitable to be deployed in a community-directed MDA programme. Previous screening work carried out by the AWOL consortium on a clinically registered drug library, provided the list of potential anti-Wolbachia drug candidates by which this thesis intends to investigate (minocycline, rifampicin, rifapentine, moxifloxacin and fusidic acid). A series of PK/PD models where constructed using data derived from well-established screening protocols, using an in-vitro cell-based assays system in conjunction with a preclinical based in-vivo model using B. malayi infected SCID mice. The results published in this thesis demonstrate that high dose rifampicin (RIF) (30 mg/Kg qd) as well as elevated rifapentine (RIP) doses (7 mg/Kg qd) could be administered using a 7-day treatment timeframe and are able to deliver a greater than 90 % reduction in Wolbachia loads. This is comparable to the current anti-Wolbachia macrofilaricide ‘gold standard’ DOX, but without the protracted 4-6 weeks treatment period. Benefits of using a rifamycin based treatment regimen are its use in both children as well as pregnant women and it could be deployed in resource-poor communities by the current health care systems that are already in place, due to the shortened treatment timeframe required. In the case of fusidic acid (FA), although it didn’t achieve the 7-day target product profile (TPP), this is not unexpected as FA is notorious for its poor bioavailability across several different species. Also, moxifloxacin (MOXI) didn’t achieve the 7-day TPP further dose optimisation studies are needed to determine the optimum dose of (MOXI) required to deliver an anti-Wolbachia macrofilaricidal affect against LF and onchocerciasis. Although ABZ didn’t have any significant affect at reducing Wolbachia loads it has recently been demonstrated to provided synergistic effects when administered with anti-Wolbachia antibiotics. These findings presented in this thesis all warrant further clinical investigation to determine the clinical efficacy of delivering a 7-day treatment regimen to determine macrofilaricidal affects against LF and onchocerciasis.

Published
2019
Full Text
View/download PDF

13. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Tomczak, Piotr, Choueiri, Toni, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas R., Hajek, Jaroslav, Lin, Tzu-Ping, Symeonides, Stefan N., Lee, Jae Lyun, Sawrycki, Piotr, Haas, Naomi B., Gurney, Howard P., Mahave, Mauricio, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Chevreau, Christine, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Topart, Delphine, Oudard, Stephane, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Quinn, David I., Alva, Ajjai, Menezes, Juliana de Janoski, Silva, Adriano Goncalves e, Winquist, Eric W., Hamzaj, Alketa, Procopio, Giuseppe, Karaszewska, Boguslawa, Nowakowska-Zajdel, Ewa M., Alekseev, Boris Y., Gafanov, Rustem A., Izmailov, Adel, Semenov, Andrey, Afanasyev, Sergey G., Lipatov, Oleg N., Powles, Thomas B., Srinivas, Sandy, McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Chung, Jinsoo, Shkolnik, Michail I., Matveev, Vsevolod B., Gajate Borau, Pablo, McCune, Steven, Hutson, Thomas E., Dri, Alejandro, Sales, Silvio Correia, Yeung, Carrie, Alcala Castro, Carmen Marcela, Bostrom, Peter, Laguerre, Brigitte, Buttigliero, Consuelo, de Giorgi, Ugo, Fomin, Eugeniy A., Zakharia, Yousef, Hwang, Clara, Singer, Eric A., Yorio, Jeffrey T., Waterhouse, David, Kowalyszyn, Ruben Dario, Alfie, Margarita Sonia, Yanez Ruiz, Eduardo, Buchler, Tomas, Kankaanranta, Krista, Ferretti, Gianluigi, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Tamada, Satoshi, Kato, Haruaki, Kitamura, Hiroshi, Danielewicz, Iwona, Wojcik-Tomaszewska, Joanna, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Rojas-Uribe, Gustavo Adolfo, Gonzalez Fernandez, Manuel Enrique, Feyerabend, Susan, Pignata, Sandro, Numakura, Kazuyuki, Cybulska Stopa, Bozena, Zukov, Ruslan, Climent Duran, Miguel Angel, Maroto Rey, Pablo Jose, Montesa Pino, Alvaro, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Cobb, Patrick W., Hauke, Ralph, Anderson, Daniel M., Sarantopoulos, John, Gourdin, Theodore, Zhang, Tian, Jayram, Gautam, Fein, Luis Enrique, Harris, Carole, Beato, Patricia Medeiros Milhomem, Flores, Francisco, Estay, Angela, Rubiano, Juan Andres, Bedke, Jens, Hauser, Stefan, Neisius, Andreas, Busch, Jonas, Anai, Satoshi, Tsunemori, Hiroyuki, Sawka, Dariusz, Sikora-Kupis, Bozena, Arranz, Jose Angel, Delgado, Ignacio, Chen, Chung-Hsin, Gunderson, Elizabeth, Tykodi, Scott, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Kaen, Diego Lucas, Sade, Juan Pablo, Tatangelo, Marcelo Daniel, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Marceau, Daniele, Paradis, Jean-Benoit, Hanna, Nawar, Acevedo, Alejandro, Ibanez, Carolina, Villanueva, Luis, Galaz, Pedro Pablo, Durango, Isabel Cristina, Manneh, Ray, Kral, Zdenek, Holeckova, Petra, Hakkarainen, Heikki, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Tartas, Sophie, Goebell, Peter J., Grimm, Marc-Oliver, Hoefner, Thomas, Wirth, Manfred, Panic, Andrej, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Mizuno, Ryuichi, Uemura, Hirotsugu, Eto, Masatoshi, Tsujihata, Masao, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Hamberg, Paul, Marczewska-Skrodzka, Malgorzata, Szczylik, Cezary, Humphreys, Alison C., Jiang, Peter, Kumar, Birendra, Lu, Gary, Desai, Arpita, Karam, Jose Antonio, Keogh, George, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Mendez, Guillermo Ariel, Harris, Samuel J., Brown, Stephen J., Antonio Junior, Joao Neif, Costamilan, Rita de Cassia, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Lalani, Aly-Khan, Graham, Jeffrey, Levesque, Michael, Orlandi, Francisco, Kotasek, Rostislav, Deville, Jean L., Borchiellini, Delphine, Merseburger, Axel, Rink, Michael, Roos, Frederik, McDermott, Ray, Oyama, Masafumi, Yamamoto, Yoshiaki, Tomita, Yoshihiko, Miura, Yuji, Ioritani, Naomasa, Westgeest, Hans, Kubiatowski, Tomasz, Bal, Wieslaw, Girones Sarrio, Regina, Rowe, Julie, Prow, Debra M., Senecal, Francis, Hashemi-Sadraei, Neda, Cole, Scott W., Kendall, Stephan D., Richards, Donald A., Schnadig, Ian D., Gupta, Mukul, Powles, Thomas, Ferguson, Thomas, Symeonides, Stefan N, Gurney, Howard, Chang, Yen-Hwa, Haas, Naomi B, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Quinn, David I, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

14. Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.

Author

Goldman, Jonathan, Waterhouse, David, George, Ben, ODwyer, Peter, Bhore, Rafia, Banerjee, Sibabrata, Lyons, Larry, Louis, Chrystal, Ong, Teng, and Kelly, Karen

Subjects
carboplatin, nab-paclitaxel, nivolumab, non-small cell lung cancer, treatment beyond progression
Abstract

Introduction: Multicenter, phase I study of concurrent and delayed nivolumab plus nab-paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC). Methods: Chemotherapy-naive patients with advanced NSCLC (ineligible for potentially curative radiation or surgery) received nab-paclitaxel 100 mg/m2 (days 1, 8, 15) and carboplatin area under the curve 6 (day 1) intravenously every 21 days (first 4 cycles); nivolumab 5 mg/kg was administered intravenously (day 15) beginning in cycle 1 (concurrent) or cycle 3 (delayed) in separate cohorts and continued beyond the 4 chemotherapy cycles. The primary objective was to assess safety. Secondary objectives were to assess tolerability and explore antitumor activity. Results: All 32 patients received chemotherapy; 20 of 22 and 6 of 10 patients also received concurrent or delayed nivolumab, respectively. No dose-limiting toxicities were reported in the concurrent cohort; 1 dose-limiting toxicity was reported in the delayed cohort. In the concurrent cohort, 20 patients (91%) had ≥1 grade 3/4 treatment-emergent adverse event (TEAE), and 7 (32%) discontinued treatment due to TEAEs. In the delayed cohort, all patients had ≥1 grade 3/4 TEAE, and 2 (20%) discontinued due to TEAEs. The median progression-free and overall survival, respectively, were 10.5 and 29.3 months in the concurrent cohort and 4.1 and 8.2 months in the delayed cohort. Conclusions: The safety profile of the combination was consistent with that of individual agents and generally similar in the 2 cohorts. Efficacy outcomes in the concurrent cohort, but not in the delayed cohort, were encouraging and support the rationale for concurrent administration of nivolumab with nab-paclitaxel/carboplatin for the treatment of advanced NSCLC. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02309177.

Published
2019

15. Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer

Author

Goldman, Jonathan W, Waterhouse, David M, George, Ben, O'Dwyer, Peter J, Bhore, Rafia, Banerjee, Sibabrata, Lyons, Larry, Louis, Chrystal U, Ong, Teng Jin, and Kelly, Karen

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Trials and Supportive Activities, Orphan Drug, Lung, Cancer, Clinical Research, Lung Cancer, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, non-small cell lung cancer, nab-paclitaxel, carboplatin, nivolumab, treatment beyond progression, Clinical sciences, Oncology and carcinogenesis
Abstract

Introduction: Multicenter, phase I study of concurrent and delayed nivolumab plus nab-paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC). Methods: Chemotherapy-naive patients with advanced NSCLC (ineligible for potentially curative radiation or surgery) received nab-paclitaxel 100 mg/m2 (days 1, 8, 15) and carboplatin area under the curve 6 (day 1) intravenously every 21 days (first 4 cycles); nivolumab 5 mg/kg was administered intravenously (day 15) beginning in cycle 1 (concurrent) or cycle 3 (delayed) in separate cohorts and continued beyond the 4 chemotherapy cycles. The primary objective was to assess safety. Secondary objectives were to assess tolerability and explore antitumor activity. Results: All 32 patients received chemotherapy; 20 of 22 and 6 of 10 patients also received concurrent or delayed nivolumab, respectively. No dose-limiting toxicities were reported in the concurrent cohort; 1 dose-limiting toxicity was reported in the delayed cohort. In the concurrent cohort, 20 patients (91%) had ≥1 grade 3/4 treatment-emergent adverse event (TEAE), and 7 (32%) discontinued treatment due to TEAEs. In the delayed cohort, all patients had ≥1 grade 3/4 TEAE, and 2 (20%) discontinued due to TEAEs. The median progression-free and overall survival, respectively, were 10.5 and 29.3 months in the concurrent cohort and 4.1 and 8.2 months in the delayed cohort. Conclusions: The safety profile of the combination was consistent with that of individual agents and generally similar in the 2 cohorts. Efficacy outcomes in the concurrent cohort, but not in the delayed cohort, were encouraging and support the rationale for concurrent administration of nivolumab with nab-paclitaxel/carboplatin for the treatment of advanced NSCLC. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02309177.

Published
2019

20. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.

Author

Ko, Andrew H, Murphy, Patrick B, Peyton, James D, Shipley, Dianna L, Al-Hazzouri, Ahmed, Rodriguez, Francisco A, Womack, Mark S, Xiong, Henry Q, Waterhouse, David M, Tempero, Margaret A, Guo, Shuangli, Lane, Cassie M, Earwood, Chris, DeBusk, Laura M, and Bendell, Johanna C

Subjects
Humans, Pancreatic Neoplasms, Paclitaxel, Albumins, Oligonucleotides, Antisense, Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols, Prognosis, Disease-Free Survival, Treatment Outcome, Adult, Aged, Middle Aged, Female, Male, HSP27 Heat-Shock Proteins, Kaplan-Meier Estimate, Oligonucleotides, Antisense, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Lessons learnedThe addition of the heat shock protein 27 (Hsp27)-targeting antisense oligonucleotide, apatorsen, to a standard first-line chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer.Findings from this trial hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation.BackgroundThis randomized, double-blinded, phase II trial evaluated the efficacy of gemcitabine/nab-paclitaxel plus either apatorsen, an antisense oligonucleotide targeting heat shock protein 27 (Hsp27) mRNA, or placebo in patients with metastatic pancreatic cancer.MethodsPatients were randomized 1:1 to Arm A (gemcitabine/nab-paclitaxel plus apatorsen) or Arm B (gemcitabine/nab-paclitaxel plus placebo). Treatment was administered in 28-day cycles, with restaging every 2 cycles, until progression or intolerable toxicity. Serum Hsp27 levels were analyzed at baseline and on treatment. The primary endpoint was overall survival (OS).ResultsOne hundred thirty-two patients were enrolled, 66 per arm. Cytopenias and fatigue were the most frequent grade 3/4 treatment-related adverse events for both arms. Median progression-free survival (PFS) and OS were 2.7 and 5.3 months, respectively, for arm A, and 3.8 and 6.9 months, respectively, for arm B. Objective response rate was 18% for both arms. Patients with high serum level of Hsp27 represented a poor-prognosis subgroup who may have derived modest benefit from addition of apatorsen.ConclusionAddition of apatorsen to chemotherapy does not improve outcomes in unselected patients with metastatic pancreatic cancer in the first-line setting, although a trend toward prolonged PFS and OS in patients with high baseline serum Hsp27 suggests this therapy may warrant further evaluation in this subgroup.

Published
2017

23. A call to action to advance patient‐focused and decentralized clinical trials

Author

Harvey, R. Donald, primary, Miller, Therica M., additional, Hurley, Patricia A., additional, Thota, Ramya, additional, Black, Lora J., additional, Bruinooge, Suanna S., additional, Boehmer, Leigh M., additional, Fleury, Mark E., additional, Kamboj, Jasmine, additional, Rizvi, Mujahid A., additional, Symington, Banu E., additional, Tap, William D., additional, Waterhouse, David M., additional, Levit, Laura A., additional, Merrill, Janette K., additional, Prindiville, Sheila A., additional, Pollastro, Teri, additional, Brewer, Jamie R., additional, Byatt, Leslie P., additional, Hamroun, Leila, additional, Kim, Edward S., additional, Holland, Nicole, additional, and Nowakowski, Grzegorz S., additional

Published
2024
Full Text
View/download PDF

29. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Author

Liu, Minetta C., Oxnard, Geoffrey R., Klein, Eric A., Smith, David, Richards, Donald, Yeatman, Timothy J., Cohn, Allen L., Lapham, Rosanna, Clement, Jessica, Parker, Alexander S., Tummala, Mohan K., McIntyre, Kristi, Sekeres, Mikkael A., Bryce, Alan H., Siegel, Robert, Wang, Xuezhong, Cosgrove, David P., Abu-Rustum, Nadeem R., Trent, Jonathan, Thiel, David D., Becerra, Carlos, Agrawal, Manish, Garbo, Lawrence E., Giguere, Jeffrey K., Michels, Ross M., Harris, Ronald P., Richey, Stephen L., McCarthy, Timothy A., Waterhouse, David M., Couch, Fergus J., Wilks, Sharon T., Krie, Amy K., Balaraman, Rama, Restrepo, Alvaro, Meshad, Michael W., Rieger-Christ, Kimberly, Sullivan, Travis, Lee, Christine M., Greenwald, Daniel R., Oh, William, Tsao, Che-Kai, Fleshner, Neil, Kennecke, Hagen F., Khalil, Maged F., Spigel, David R., Manhas, Atisha P., Ulrich, Brian K., Kovoor, Philip A., Stokoe, Christopher, Courtright, Jay G., Yimer, Habte A., Larson, Timothy G., Swanton, Charles, Seiden, Michael V., Cummings, Steven R., Absalan, Farnaz, Alexander, Gregory, Allen, Brian, Amini, Hamed, Aravanis, Alexander M., Bagaria, Siddhartha, Bazargan, Leila, Beausang, John F., Berman, Jennifer, Betts, Craig, Blocker, Alexander, Bredno, Joerg, Calef, Robert, Cann, Gordon, Carter, Jeremy, Chang, Christopher, Chawla, Hemanshi, Chen, Xiaoji, Chien, Tom C., Civello, Daniel, Davydov, Konstantin, Demas, Vasiliki, Desai, Mohini, Dong, Zhao, Fayzullina, Saniya, Fields, Alexander P., Filippova, Darya, Freese, Peter, Fung, Eric T., Gnerre, Sante, Gross, Samuel, Halks-Miller, Meredith, Hall, Megan P., Hartman, Anne-Renee, Hou, Chenlu, Hubbell, Earl, Hunkapiller, Nathan, Jagadeesh, Karthik, Jamshidi, Arash, Jiang, Roger, Jung, Byoungsok, Kim, TaeHyung, Klausner, Richard D., Kurtzman, Kathryn N., Lee, Mark, Lin, Wendy, Lipson, Jafi, Liu, Hai, Liu, Qinwen, Lopatin, Margarita, Maddala, Tara, Maher, M. Cyrus, Melton, Collin, Mich, Andrea, Nautiyal, Shivani, Newman, Jonathan, Newman, Joshua, Nicula, Virgil, Nicolaou, Cosmos, Nikolic, Ongjen, Pan, Wenying, Patel, Shilpen, Prins, Sarah A., Rava, Richard, Ronaghi, Neda, Sakarya, Onur, Satya, Ravi Vijaya, Schellenberger, Jan, Scott, Eric, Sehnert, Amy J., Shaknovich, Rita, Shanmugam, Avinash, Shashidhar, K.C., Shen, Ling, Shenoy, Archana, Shojaee, Seyedmehdi, Singh, Pranav, Steffen, Kristan K., Tang, Susan, Toung, Jonathan M., Valouev, Anton, Venn, Oliver, Williams, Richard T., Wu, Tony, Xu, Hui H., Yakym, Christopher, Yang, Xiao, Yecies, Jessica, Yip, Alexander S., Youngren, Jack, Yue, Jeanne, Zhang, Jingyang, Zhang, Lily, Zhang, Lori (Quan), Zhang, Nan, Curtis, Christina, Berry, Donald A., Liu, M.C., Oxnard, G.R., Klein, E.A., Swanton, C., and Seiden, M.V.

Published
2020
Full Text
View/download PDF

30. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Author

Agajanian, Richy, Ahmad, Rizvana, Aktas, Bahriye, Alencar, Victor Hugo, Amadori, Dino, Andrade, Jurandyr, André Franke, Fábio, Angiolini, Catia, Aogi, Kenjiro, Armor, Jess, Arpornwirat, Wichit, Assersohn, Laura, Audeh, William, Aulitzky, Walter, Azevedo, Sergio, Bartoli, Maria Alejandra, Batista Lopez, Norberto, Bianconi, María, Biganzoli, Laura, Birhiray, Ruemu, Bitina, Marianna, Blachy, Ron, Blackwell, Kimberly, Blanchard, Rita, Blanchet, Paulette, Boiangiu, Ion, Bower, Barbara, Brezden-Masley, Christine, Brufsky, Adam, Budde, Leanne, Caguioa, Priscilla, Calvo, Lourdes, Campone, Mario, Carroll, Robert R., Castro, Hugo, Chan, Valorie, Charu, Veena, Cinieri, Saverio, Clemens, Michael, Conejo, Emilio Alba, Côrtes, Eduardo, Coudert, Bruno, Cronemberger, Eduardo, Cubero, Daniel, Dakhil, Shaker, Daniel, Brooke, Davidson, Neville, De Fatima Gaui, Maria, De La Cruz, Susana, Del Pilar, Maria, Delgado, Gilson, Ellerton, John A., Estuardo, Cesar, Fehrenbacher, Louis, Ferrero, Jean-Marc, Flynn, Patrick J., Foszczynska-Kloda, Malgorzata, Franco, Sandra, Fujii, Hirofumi, Gallagher, Chris, Gamucci, Teresa, Giacomi, Nora, Gil I Gil, Miguel, Gonzalez Martin, Antonio, Gorbunova, Vera, Gotovkin, Eugeny, Green, Nathan, Grincuka, Elza, Grischke, Eva-Maria, Hansen, Vincent, Hargis, Jeffrey, Hauschild, Maik, Hegg, Roberto, Hendricks, Carolyn, Hermann, Robert, Hoff, Paulo, Horiguchi, Jun, Hornedo Muguiro, Javier, Iacobelli, Stefano, Inoue, Kenichi, Ismael, Gustavo, Itoh, Yoshinori, Iwata, Dr Hiroji, Jendiroba, Davi, Jochim, Rosa, Jones, Alison, Just, Marianne, Kallab, Andre, Karwal, Mark, Kashiwaba, Masahiro, Kato, Giraldo, Kaufman, Peter A., Kellokumpu-Lehtinen, Pirkko, Kirsch, Andreas, Kiselev, Igor, Klein, Paula, Kohno, Norio, Kopp, Mikhail, Kostovska-Maneva, Liljana, Kotliar, Mauricio, Kudaba, Iveta, Kümmel, Sherko, Kuroi, Katsumasa, Lacava, Juan, Latini, Luciano, Lee, Soo Chin, Lichinitser, Mikhail, Lobo, Christopher, Maintz, Christoph, Maneecahvakajorn, Jedzada, Marmé, Alexander, Martinez, Gloria, Masuda, Norikazu, Matwiejuk, Mario, Merculov, Vladimir, Michaelson, Richard, Miguel, Luis, Monroy, Hernandez, Montemurro, Filippo, Morales, Serafin, Moura, Rodrigo, Mueller, Volkmar, Mulatero, Clive, Nakagami, Kazuhiko, Nakayama, Takahiro, Neidhart, Jeff, Nguyen, An, Nishimura, Reiki, Ogata, Haruki, O'reilly, Susan, O'rourke, Timothy, Otero Reye, Douglas, Ouyang, Xuenong, Patel, Ravi, Patel, Taral, Pedrini, Jose Luiz, Pereira, Rodrigo, Perez, Alejandra, Peterson, Carol, Pienkowski, Tadeusz, Pinczowski, Helio, Polikoff, Jonathan, Polkowski, Wojciech, Price, Paola Edith, Prill, Sue, Priou, Frank, Purkalne, Gunta, Pyrhoenen, Seppo, Quackenbush, Robert, Rai, Yoshiaki, Ribelles, Nuria, Ro, Jungsil, Robinson, Anne, Robles, Robert, Rodriguez, Gladys, Roman, Laslo, Saji, Shigehira, Sanchez-Rovira, Pedro, Sato, Nobuaki, Schmidt, Marcus, Schumacher, Claudia, Senecal, Frank, Sharma, Priyanka, Shen, Zhenzhou, Shirinkin, Vadim, Simoncini, Edda, Sirisinha, Thitiya, Smith, Raymond, Sohn, Joo-Hyuk, Soldic, Zeljko, Soria, Tania, Spicer, Darcy, Srimuninnimit, Vichien, Sriuranpong, Virote, Staroslawska, Elzbieta, Stefanovski, Petar, Sunpaweravong, Patrapim, Taguchi, Julie, Takeda, Koji, Tellez-Trevilla, Gabriel, Thomas, Randall, Thomssen, Christoph, Toache, Zetina, Tokuda, Yutaka, Tomczak, Piotr, Tosello, Celia, Tsugawa, Koichiro, Tudtud, Dennis, Ueno, Takayuki, Van Eyll, Brigitte, Varela, Mirta, Vasev, Nikola, Vrbanec, Damir, Wang, Xiaojia, Wang, Liwei, Watanabe, Junichiro, Waterhouse, David, Wesenberg, Birgitta, Wheatley, Duncan, Wong, Zee Wan, Yadav, Sanjay, Yardley, Denise, Yau, Tsz-Kok, Yeo, Winnie, Ying, Cheng, Youn Oh, Do, Swain, Sandra M, Miles, David, Kim, Sung-Bae, Im, Young-Hyuck, Im, Seock-Ah, Semiglazov, Vladimir, Ciruelos, Eva, Schneeweiss, Andreas, Loi, Sherene, Monturus, Estefanía, Clark, Emma, Knott, Adam, Restuccia, Eleonora, Benyunes, Mark C, and Cortés, Javier

Published
2020
Full Text
View/download PDF

31. Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry

Author

Mileham, Kathryn F., Bruinooge, Suanna S., Aggarwal, Charu, Patrick, Alicia L., Davis, Christiana, Mesenhowski, Daniel J., Spira, Alexander, Clayton, Eric J., Waterhouse, David, Moore, Susan, Jazieh, Abdul-Rahman, Chen, Ronald C., Kaltenbaugh, Melinda, Williams, Jen Hanley, Gralow, Julie R., Schilsky, Richard L., and Garrett-Mayer, Elizabeth

Published
2021
Full Text
View/download PDF

35. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

Author

Spigel, David R., McCleod, Michael, Jotte, Robert M., Einhorn, Lawrence, Horn, Leora, Waterhouse, David M., Creelan, Ben, Babu, Sunil, Leighl, Natasha B., Chandler, Jason C., Couture, Felix, Keogh, George, Goss, Glenwood, Daniel, Davey B., Garon, Edward B., Schwartzberg, Lee S., Sen, Rohini, Korytowsky, Beata, Li, Ang, Aanur, Nivedita, and Hussein, Maen A.

Published
2019
Full Text
View/download PDF

37. Integration of Genetic Testing and Counseling in Patients With Breast Cancer in a Large, Multisite Community-Based Practice.

Author

Mendenhall, Molly A., Guinigundo, Andrew, Davies, Dan, Ward, Patrick, Drosick, David R., and Waterhouse, David M.

Subjects
CANCER patient psychology, GENETIC testing, MEDICAL protocols, DESCRIPTIVE statistics, RESEARCH funding, GENETIC counseling, BREAST tumors
Abstract

PURPOSE Despite data-driven consensus recommendations, there remains significant nonadherence to genetic screening and testing. More than 300,000 patients are diagnosed with breast cancer annually, with one third of these estimated to be eligible for homologous recombination deficiency (HRD)/BRCA testing following National Comprehensive Cancer Network (NCCN) guidelines. Only 35% of eligible patients are referred for genetic counseling. METHODS The goal of this project was to apply NCCN guidelines for germline genetic testing to all new patients with breast cancer within a large community oncology practice to improve HRD/BRCA testing. Plan-Do-Study-Act methodology was used, and cycles were built on a proven teaching infrastructure. In cycle 1, providers were educated and directed to use electronic health record (EHR) templates in the setting of an initial diagnosis visit and treatment planning. Discreet data fields were created in the EHR during cycle 2 to streamline and automate the process. Appropriate patients were referred to the genetics team for further evaluation, counseling, and testing. Adherence to the plan was maintained and measured using data analytic reports and chart audits. RESULTS Of the 1,203 patients with breast cancer eligible for inclusion, 1,200 (99%) were screened according to NCCN guidelines. Of the screened patients, 631 (52.5%) met the referral/testing criteria. In total, 585 (92.7%) of the 631 were referred to a genetic specialist. Seven percent had previous referrals. A total of 449 (71%) patients were acceptable to genetics referral while 136 (21.5%) patients refused. CONCLUSION The implementedmethods of education, NCCN guidelines imbedded within provider notes, and discreet data fields in the EHR have proven to be highly effective in screening appropriate patients and ordering subsequent genetic referrals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Nocturnal visits of flying-foxes to an English Oak.

Author

Mo, Matthew and Waterhouse, David R.

Subjects
ENGLISH oak, DECIDUOUS plants, ORNAMENTAL trees, TREE crops
Abstract

This article discusses the presence of flying-foxes in a suburban backyard in Sydney, specifically focusing on their visits to an English Oak tree during the months when acorns are produced. The authors observed the flying-foxes, but it is unclear whether they were feeding on the acorns or using the tree as a roosting site. The article provides general information on the diet and foraging habits of flying-foxes, as well as the characteristics of the English Oak tree. Additionally, the text describes observations made during a spotlighting search in the Blue Gum Swamp track of the Blue Mountains National Park on November 3, 2023, during which there was some rainfall. The information is sourced from The Victorian Naturalist. [Extracted from the article]

Published
2024

39. Albendazole and antibiotics synergize to deliver short-course anti- Wolbachia curative treatments in preclinical models of filariasis

Author

Turner, Joseph D., Sharma, Raman, Al Jayoussi, Ghaith, Tyrer, Hayley E., Gamble, Joanne, Hayward, Laura, Priestley, Richard S., Murphy, Emma A., Davies, Jill, Waterhouse, David, Cook, Darren A. N., Clare, Rachel H., Cassidy, Andrew, Steven, Andrew, Johnston, Kelly L., McCall, John, Ford, Louise, Hemingway, Janet, Ward, Stephen A., and Taylor, Mark J.

Published
2017

40. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial

Author

Smit, Menno R, Ochomo, Eric O, Aljayyoussi, Ghaith, Kwambai, Titus K, Abong'o, Bernard O, Chen, Tao, Bousema, Teun, Slater, Hannah C, Waterhouse, David, Bayoh, Nabie M, Gimnig, John E, Samuels, Aaron M, Desai, Meghna R, Phillips-Howard, Penelope A, Kariuki, Simon K, Wang, Duolao, Ward, Steve A, and ter Kuile, Feiko O

Published
2018
Full Text
View/download PDF

44. Figure S6. Serum Cytokines (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

45. Figure S2. Survival Outcomes By Tumor PD-L1 Levels (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Data from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

47. Figure S4 from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

48. Figure S5. Tumor Epithelial/Stromal Compartment CD8+ T-Cell Ratio in Tissue-Matched Metastatic Tumors (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

49. Figure S1. Study Design from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

50. Figure S3. Peripheral T-Cell Proliferation on Treatment (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results